A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY.
Latest Information Update: 15 Sep 2023
At a glance
- Drugs RT 001 (Primary)
- Indications Progressive supranuclear palsy
- Focus Therapeutic Use
- Sponsors Retrotope
- 09 Feb 2023 Status changed from active, no longer recruiting to completed.
- 09 Feb 2023 This trial has been completed in Poland (Global end date: 2022-08-29), according to European Clinical Trials Database record.
- 28 Jan 2023 This trial has been completed in Hungary (Global end date: 2022-08-29), according to European Clinical Trials Database record.